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Abstract
Inconsistent reports on the therapeutic efficacy of increasing synaptic glycine
concentration have raised doubt as to the benefit of N-methyl-D-aspartate
receptor (NMDAr) mediated treatments for schizophrenia. Categorising
individuals based on broad diagnostic criteria does not appear to adequately
identify individuals who will benefit from such treatments. Mismatch negativity
(MMN) may be a suitable biomarker of NMDAr function, to help clarify the
neurobiological relationship between pharmacological intervention and clinical
treatment efficacy. MMN is an auditory event-related potential elicited following
the presentation of a deviant stimulus, when it violates an established sequence
stored in echoic memory. MMN is a robust deficit in schizophrenia and is
categorised as a physiological element in the Cognitive Systems domain of the
Research Domain Criteria framework. However, few studies have examined direct
pharmacological modulation of MMN in schizophrenia patients. The aim of this
thesis was to determine the nature of the relationship between MMN and NMDAr
function, to inform the relative utility of MMN as a biomarker of NMDAr-mediated
improvements in clinical symptoms in schizophrenia. To achieve this aim, three
separate empirical studies were performed.
Study one aimed to determine the nature of the relationship between
regular cannabis exposure and MMN in otherwise healthy subjects. A crosssectional comparison between regular cannabis users and controls was used to
infer the effects of regular cannabis exposure on endocannabinoid-mediated
alterations in NMDAr excitability. Frequency MMN amplitude was smaller in the
iv

overall sample of regular users and smaller duration MMN amplitude was linearly
associated with more prolonged and heavier cannabis exposure. These findings
suggest regular cannabis use alters cannabinoid receptor type-I (CB1) mediated
inhibition of NMDArs in auditory cortical networks important for MMN
generation. Further, they suggest regular use alters neurobiological function in
target pathways of NMDAr-mediated treatments. This is problematic when
interpreting MMN deficits as pathophysiological correlates of core phenotypes
and may confound NMDAr-mediated treatment efficacy in schizophrenia.
Study two aimed to determine whether acute glycine administration and
adjunct glycine treatment increases MMN generation in chronic schizophrenia
patients. In a randomised, double-blind, placebo-controlled, between-group trial,
acute administration of low-dose glycine (0.2g/kg) increased MMN amplitude
compared to placebo. Smaller duration MMN amplitude at baseline was linearly
associated with greater severity of negative symptoms and predicted, at trend
level, the degree of negative symptom improvement following 6-weeks of glycine
treatment (incremented to 0.6g/kg/day). These findings support the view that
NMDAr hypofunction contributes to robust MMN deficits observed in
schizophrenia and demonstrates that MMN is a sensitive index of NMDAr
hypofunction related to the pathophysiology of negative symptoms. Further,
these findings support the utility of MMN to stratify neurobiological functioning
of NMDArs and index change in neuronal function following target engagement of
NMDAr-mediated treatments.
Study three aimed to determine the dose-response relationship between
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glycine and MMN, in a randomised, double-blind, placebo-controlled, crossover
trial. In an independent sample of healthy controls, this study observed an
Inverted-U dose-response relationship between glycine dose and MMN
amplitude. High-dose glycine (0.8g/kg) reduced MMN amplitude compared to
low- and medium-doses (0.2g/kg and 0.4g/kg, respectively), but did not differ from
placebo. Smaller baseline MMN amplitude was associated with greater increases
in MMN following low-dose glycine, suggesting that increasing synaptic glycine
concentration is more beneficial in the context of NMDAr remediation. These
findings support MMN as a sensitive biomarker indexing change in NMDAr
function and may help to inform mechanisms of clinical treatment efficacy
following increased synaptic glycine concentrations.
Findings in this thesis support the utility of MMN to index NMDAr function
and change in neuronal signalling following target engagement of NMDArmediated treatments. Alterations in MMN generation in regular cannabis users
suggest MMN is sensitive to long-term plasticity changes in auditory-cortical
networks. The efficacy of glycine to improve NMDAr neurotransmission in this
thesis (indexed by MMN) appears to be mediated by NMDAr function prior to
glycine administration and glycine dose amount. These findings support the
potential for MMN to identify conditions for optimal treatment efficacy. Future
studies confirming the presence of an Inverted-U dose-response relationship
between MMN and other NMDAr agents, such as glycine reuptake inhibitors, may
assist in tailoring effective treatments and better inform mechanisms of treatment
heterogeneity in schizophrenia.
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Chapter One
Schizophrenia

Schizophrenia

Chapter Introduction
Since the development of antipsychotics in the early 1970’s, little progress has
been made to improve drug efficacy and tolerability in schizophrenia, particularly
in managing negative symptoms and cognitive deficits. Non-adherence to
pharmacotherapy is approximately 50% in patients [1] and approximately one
third do not respond to standard medications [2]. There is currently a lack of
treatment available to increase motivation, emotional experience, attention,
thought processes and ability to make judgements. Negative symptoms and
cognitive deficits are evident in the prodromal phase and are associated with poor
functional outcome and reduced quality of life in later stages of illness [3]. Greater
understanding of the mechanisms underlying these core refractory symptoms
may yield earlier diagnosis and improve symptom management for many patients.
The following chapter defines schizophrenia as a clinical disorder, before
reviewing the underlying biological mechanisms of core phenotypes. The primary
theoretical models of neurotransmitter dysfunction provide a framework to
discuss the utility of novel N-methyl-D-aspartate receptor (NMDAr) mediated
treatments, which aim to increase glutamatergic function. Given the role of the
endocannabinoid system in regulating NMDArs and alterations in this regulatory
mechanism following repeated cannabis use, the effects of cannabis in relation to
the pathophysiology of clinical symptoms in schizophrenia are also discussed. The
chapter concludes by identifying the need for biomarkers in schizophrenia to
inform mechanisms of treatment heterogeneity following pharmacological
invention with NMDAr-mediated treatments.
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Schizophrenia Disorder
Schizophrenia is a chronic and debilitating mental disorder and is one of the most
severe in terms of personal suffering and societal burden. The prevalence of
schizophrenia is approximately 0.30-0.66 cases per 1,000 people, with an
incidence of 10.2-22.0 new cases per 100,000 people, per year [4, 5]. Typical onset
occurs in late adolescence or early adulthood, with an initial diagnosis at
approximately 26 years in males and 30 years in females (for further review, see
[6]). The behavioural phenotypes of schizophrenia cause great disruptions and
suffering in the day-to-day life of patients, including reduced functional capacity,
lower financial stability, increased health care needs, shorter life expectancy [7-9]
and overall reduced quality of life [3]. The chronic nature of the syndrome also
generates significant financial burden to the community [10], with an annual cost
reported in Australia, for example, of approximately $2.6 billion in 2013 [5].
Two of the most widely used diagnostic criteria for validating the profile of
schizophrenia are the Diagnostic and Statistical Manual (Version 10; DSM-V) [11],
and the International Statistical Classification of Disease and Related Health
Problems (Version 10; ICD-10) [12]. Characteristics of symptoms in the DSM-V are
divided into two broad symptom domains: positive and negative symptoms.
Although not included in the diagnostic criteria, neurocognitive decline is also
considered a core feature of functional disability in schizophrenia [11, 13] and
characterises the deteriorating nature of the disorder. Due to limited diagnostic
stability, diverse treatment outcomes and discrete longitudinal course, the
subtypes of schizophrenia have been removed from the DSM-V and replaced with
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a dimensional structure, focusing on the stage and severity of presenting
symptoms [14]. Classifying core phenotypes in a dimensional framework may offer
greater predictive power for clinical outcomes [15], particularly when
investigating clinical treatment efficacy of pharmacotherapies or behavioural
interventions.

1.2.1 Positive Symptoms
The manifestation of schizophrenia is generally characterised by the onset of
positive symptoms, which tend to be episodic over time and associated with
increased risk of self-harm and hospitalisation [16]. Positive symptoms are an
exacerbation of normal functioning, including delusions, hallucinations,
disorganised thought and disorganised or catatonic behaviour [17]. Delusions are
often conceptualised as misinterpretations of other people’s intentions or beliefs
and are regularly associated with an area of personal reference or significance.
Patients may experience hallucinations or perceptual abnormalities in a range of
uni- or multi-modal sensory systems, including olfactory, visual, gustational, and
somatic [18]. Speech and thought patterns may often become incoherent or
illogical, where the content of one topic does not contextually link to the next, or
the original content of the thought is forgotten. The positive symptoms of
schizophrenia often make it difficult for patients to identify components of their
experience that are not part of reality.
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1.2.2 Negative Symptoms
The manifestation of negative symptoms may precede the onset of the first
psychotic episode and when pronounced during prodromal stages of illness,
contribute to poorer clinical prognosis and long-term disability [19]. Negative
symptoms are pervasive throughout the disorder, more stable over time and
follow a longitudinally independent course when compared to positive symptoms
[20]. The negative dimension of schizophrenia is characterised by absent or
diminished emotional and behavioural responses, such as alogia (reduced quality
or quantity of speech), avolition (reduced ability to initiate and follow through on
plans), anhedonia (lack of pleasure), flattened affect (expressed as monotonous
voice tone or immobile facial expressions) and social withdrawal (loss of interest
in social engagement) [11]. The persistent nature of these symptoms impairs a
patient’s ability to maintain daily functioning and is associated with cognitive
decline [21], an arrest in social development and attainment in usual social roles
[22]. Despite a strong association, the shared variance between negative
symptoms and cognitive deficits has been shown to be small, suggesting that each
domain contributes independently to reduced functional outcomes [23].

1.2.3 Cognitive Deficits
Neurocognitive decline in schizophrenia represents a moderate-to-severe
deviation below the norm [24] in areas important for daily functioning, including
memory, learning, attention, visuo-spatial abilities, language and executive
function [25-27]. Some patients present with reduced cognitive performance prior
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to the onset of illness [28] and by the time of onset of the first psychotic episode,
show stable impairment in several domains [29]. Cognitive deficits are associated
with reduced ability to perform daily living tasks [30, 31] and reduced measures
of global functioning and quality of life [3]. These debilitating performance
outcomes remain consistent throughout chronic stages of illness in most patients
[29]. Behavioural deficits may be indicative of abnormal neuronal development,
aberrant neuroplasticity, structural and functional alterations [32], or
unexpressed genetic components [33-36]. Conceptualising schizophrenia as a
syndrome of cognitive dysfunction remains a core focus of clinical research, in an
attempt to clarify the underlying mechanisms that give rise to and maintain these
disabling features of the disorder.

Pathophysiology of Schizophrenia
Advances in molecular biology, genetics and imaging techniques provide evidence
of alterations in several neurotransmitter systems, including dopamine,
glutamate, gamma-aminobutyric acid (GABA) and serotonin, which link abnormal
neurochemistry to the phenotypic expressions of schizophrenia. These
neurobiological frameworks aim to accommodate structural and functional
abnormalities and disconnectivity between brain regions. The dopamine
hypothesis of schizophrenia still remains the most relevant theory linking the
pathophysiology of positive symptoms to the mechanism of current antipsychotic
medications. However, the development of the glutamatergic hypothesis
reconceptualised our understanding of the disorder and offers a new mechanism
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of action and potential neurobiological target for treating core refractory
symptoms. While these models are still in their infancy in explaining the aetiology
of schizophrenia, their contribution to a neuropathophysiological framework of
the brain usefully informs the manifestation and maintenance of core phenotypes.
Further investigation and ongoing refinement of these models continues to
advance the development of novel treatment interventions and their progression
into clinical trials.

1.3.1 Dopamine Hypothesis
The initial hypothesis of excessive subcortical dopamine was derived from clinical
benefits following administration of antipsychotics [37] and their potency for
dopamine type-II (D2) receptors [38]. Neuroimaging studies provide evidence of
D2 receptor hyperfunction in the mesolimbic pathway projecting from the ventral
tegmental area to the nucleus accumbens [39] (Figure 1.1a). This increase in
dopaminergic neurotransmission is associated with increased positive symptoms
in schizophrenia and parallels fluctuations in psychotic episodes throughout the
course of illness [40]. D2 receptors are highly concentrated in the striatum, with
lower concentrations in the prefrontal cortex and medial temporal regions.
Dopamine dysfunction in the striatum, which receives inputs from both the
ventral tegmental area and nucleus accumbens (Figure 1.1b), has been proposed
as a final common pathway and mechanism of positive psychotics symptoms [41].
Overactive D2 receptor expression in this region may also contribute to corticalmediated cognitive deficits observed in schizophrenia [42].
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Figure 1.1. Mesolimbic and mesocortical pathways related to the dopamine hypothesis of schizophrenia: a) over-active dopaminergic
function in the mesolimbic pathway, projecting from the ventral tegmental area to the nucleus accumbens, contributes to the manifestation
of positive symptoms; b) the striatum is highly dense in dopamine D2 receptors, receiving input from the ventral tegmental area and nucleus
accumbens, and is the proposed final common pathway of positive symptoms in schizophrenia; c) under-active dopaminergic
neurotransmission in the mesocortical pathway contributes to the manifestation of negative symptoms and cognitive deficits. DLPFC,
dorsolateral prefrontal cortex; NA, nucleus accumbens; PFC, prefrontal cortex; STR, striatum; VTA, ventral tegmental area.
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Hypoactivation of dopamine in the mesocortical pathway (Figure 1.1c) may
play an important role in the generation of negative symptoms and cognitive
impairment [43-46]. Activation of dopamine type-I (D1) receptors located on
glutamatergic neurons decreases presynaptic glutamate release, while those
located on GABA interneurons promote inhibition of pyramidal neurons [47, 48].
Reduced D1 receptor binding in the prefrontal cortex has been observed in drugnaïve schizophrenia patients and has shown to be associated with increased
severity of negative symptoms and impaired cognitive performance [49]. Despite
these associations, the dopamine hypothesis is limited to defining a
pathophysiological understanding of psychosis. This neurobiological model is less
able to define the aetiology of other neurotransmitter system dysfunction, such
as glutamate, adenosine and serotonin, which accommodate broader phenotypic
profiles in schizophrenia [50].

1.3.2 Glutamate Hypothesis
Decreased NMDAr function is thought to underlie neuronal atrophy and reduced
excitatory networks in schizophrenia [51, 52]. The glutamatergic hypothesis
proposes a preliminary dysregulation in prefrontal NMDAr function, which alters
downstream dopaminergic neurotransmission [53, 54]. Hypofunctional NMDArs
in the prefrontal cortex result in a weak GABA tone, attenuating the inhibition of
secondary glutamate release (Figure 1.2). Increased secondary glutamate leads to
excessive release of dopamine in the mesolimbic pathway (for further review, see
[55]). This theory accommodates positive symptoms that are synonymous with
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the dopamine hypothesis, as well as providing a neurobiological model inclusive
of negative symptoms, cognitive deficits and additional structural and functional
alterations reported in schizophrenia.
Support for glutamate dysfunction comes from acute models of
dissociative anaesthetics that block NMDArs and decrease glutamate availability
in the prefrontal cortex. NMDAr antagonists such as Phencyclidine (PCP) and
Ketamine have been shown to give rise to schizophrenia-like symptoms in
individuals without psychiatric history [51, 56] and worsen symptoms in
schizophrenia patients [57, 58]. These acute pharmacological models induce
positive and negative symptoms in a dose-response manner [59] and model
cognitive impairments [53, 60], thought disorder [61] and eye tracking
abnormalities [62, 63] that are reminiscent of schizophrenia. NMDAr co-agonists,
such as glycine, have shown to inhibit PCP-induced hyperactivity [64], providing
further evidence of altered NMDAr function underlying core schizophrenia
phenotypes.
Patient studies report decreased glutamate levels in cerebrospinal fluid
and increased NMDArs post-mortem [65]. This increase in NMDArs is likely a
neuronal compensatory mechanism to manage the pervasive state of decreased
glutamatergic function, which is evident throughout the chronicity of the disorder
[66]. Individuals with complete dopamine D2 receptor blockade persist with
positive symptoms [67], suggesting that psychosis is mediated by additional
neurotransmitter networks beyond hyperactive dopaminergic function in the
mesolimbic pathway. Contrary to these conclusions, research utilising magnetic
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Figure 1.2. Schematic illustration of the glutamatergic hypothesis of
schizophrenia.

N-methyl-D-aspartate receptor-mediated positive symptoms,

negative symptoms and cognitive deficits in the glutamatergic model of
schizophrenia. NMDA, N-methyl-D-aspartate; GABA, Gamma-Aminobutyric Acid.

11

Schizophrenia

resonance spectroscopy techniques have failed to identify a consistent
relationship between regional glutamate and glutamine levels across different
stages of the disorder (for further review, see [68]). In order to inform the
aetiology and maintenance of core refractory symptoms, there is need to clarify
their relationship with the pathophysiology of altered NMDAr function in cortical
and subcortical networks within the brain.

1.3.2.1 Glutamatergic Neurotransmitters
At resting potential, NMDArs are ligand-gated ion channels blocked by a
magnesium (Mg2+) gate. This block is relieved when the membrane potential is
depolarised, allowing an influx of calcium (Ca2+) to enter the neuron. For NMDArs
to be activated, they require glycine (an NMDAr co-agonist) to bind to the NR1
subunit and glutamate to bind to the NR2 subunit of the receptor. When this
occurs, Ca2+ activates a second messenger system that alters pre- and postsynaptic connections via long-term potentiation and long-term depression (for
further review, see [69]). It is through this change in synaptic connection strength
by which the brain learns and encodes new information. High levels of
extracellular sodium (Na+) and high intracellular potassium (k+) concentrations
allow Na+ pumps to reabsorb glutamate and amino acids back into the cell.
Glutamate is either reabsorbed via this process or it is converted into glutamine
by glial cells and transported to other neurons [70], before being converted back
into glutamate. When high levels of glutamate accumulate outside of the cell and
are not reabsorbed, NMDArs are re-activated, allowing further influx of Ca2+ ions
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to enter the cell. This increased concentration of intracellular Ca2+ may lead to
neuronal cell death or excitotoxicity and is likely a contributing factor of neuronal
atrophy observed in schizophrenia [71].

1.3.2.2 GABAergic Neurotransmitters
Attention to GABAergic function in schizophrenia was rejuvenated following
developments in dopaminergic and glutamatergic hypotheses. GABAergic neurons
contribute to a holistic framework of both deficits [72] and potential therapeutic
interventions [73] in schizophrenia. This is particularly relevant to understanding
alterations in neuronal plasticity within the disorder, as both glutamate and GABA
play an important role in filtering information transmitted to cortical pyramidal
neurons. When information is transferred down the neuronal dendritic spine,
GABAergic synapses moderate neuronal plasticity by filtering glutamatergic
signals, before they propagate to the cell soma to generate an action potential (for
further review, see [74]; Figure 1.3). Glutamatergic neurons provide the excitatory
drive for GABAergic interneurons, whereby reduced glutamatergic function leads
to a loss of inhibitory filtering and subsequent hyper-activation of pyramidal
neurons (Figure 1.2). Therefore, reduced cortical function of glutamate may
initiate GABA-mediated cognitive deficits in schizophrenia.

Neurobiological Alterations
A structural model of schizophrenia is supported by findings of smaller whole brain
volume [75, 76], reduced hippocampal volume [77], decreased grey matter
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.

Figure 1.3. Gamma-aminobutyric acid filtering of pyramidal neurons. GammaAminobutyric Acid (GABA) interneurons filter (green vertical bar) excitatory inputs
on the dendritic spines of cortical pyramidal neurons, before reaching the cell
soma. When glutamatergic regulation of GABA interneurons is decreased, the
GABA-mediated inhibitory filtering is reduced, resulting in hyper-activation of
cortical pyramidal neurons. GABA, Gamma-Aminobutyric Acid.
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[75, 78, 79], enlarged ventricles [80], focal alterations of white matter tracts and
brain atrophy in regions such as the prefrontal cortex [16]. Alterations in structural
and functional connectivity appear evident across different stages of the disorder
[81, 82] , while structural alterations in family members provide support for a
genetic contribution (for further review, see [83]). Findings of neurobiological
alterations in schizophrenia has facilitated the characterisation of different stages
of the disorder, including the development of premorbid risk factors (for further
review, see [84]). Individuals at high risk for developing psychosis are reported to
have pronounced grey matter deficits [85], reduced whole brain volume, and left
and right prefrontal and temporal lobe volume [76]. Diffusion tensor imaging
techniques report that abnormal white matter development in temporal regions
in schizophrenia predicts functional outcomes in later stages of illness [86].
Neuroscience has directed much attention to understanding phenotypes
arising from aberrant neuronal networks and integration between brain regions,
suggesting that many phenotypes can only be explained by considering the
relationship between a range of cognitive processes. Instead of attributing
structural plasticity, symptoms are postulated to result from synaptic plasticity the activity dependent modelling of the pattern and strength of synaptic
connections (for further review, see [87]). A series of post-mortem studies report
reduced excitatory feed-forward circuits extending from the auditory cortex (AC)
in chronic patients [88, 89], which may result in poor adaptation to perceptual
changes in the environment. A disconnectivity framework of schizophrenia
proposes that the brain may still show regionally specific structural abnormalities,
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but that these abnormalities are secondary to the more pervasive problem of
deficient integration and communication of information [87].

Antipsychotic Treatments
In the acute psychotic state, schizophrenia patients exhibit an increase in
dopamine synthesis and synaptic dopamine concentration [90], providing a clear
and logical link to first-generation antipsychotics (FGAs) targeting dopamine D2
receptor function [91]. A limitation of FGAs, which includes agents such as
haloperidol and chlorpromazine, is the manifestation of extrapyramidal side
effects following acute and chronic D2 receptor blockade (Figure 1.4). Following
administration of haloperidol, dopamine D2 receptor occupancy rates above 65%
have demonstrated therapeutic efficacy, while occupancy rates above 78%
elicited extrapyramidal side-effects and no further symptom improvement [91].
High doses of FGAs can also block activation in the mesocortical pathway,
contributing to secondary negative symptoms and cognitive deficits [92].
The profound side effects of FGAs led to the development of secondgeneration antipsychotics (SGAs). An advantage of SGAs is reduced specificity for
dopaminergic receptors and indirect modulation of dopamine via other
neurotransmitter systems. For example, risperidone and ziprasidone have a high
affinity ratio for 5HT2A-to-D2 receptors, where 5HT2A has an additional regulatory
effect on dopaminergic function (for example, see [93, 94]). These properties
allow the drugs to maintain their therapeutic benefit while lowering the risk of
extrapyramidal and secondary negative symptoms. Contrary to the proposed
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benefits of SGAs, these drugs also incur increased cardio and metabolic sideeffects, such as weight gain and glucose dysregulation (for further review, see
[95]). Overall, these treatments have not met expectations with regards to
reduced side-effect profiles or increased tolerability when directly compared to
FGAs (for further review, see [96]).
Clozapine is almost considered a third class of antipsychotic, due to its
ability to treat up to 50-60% of treatment-refractory patients (i.e. patients who
have not previously responded to antipsychotic medication) [94, 97]. However,
this drug demonstrates limited efficacy when administered to treat first episode
psychosis [98]. Clozapine has lower-affinity and short-term high occupancy at D2
receptors, which is sufficient to maintain antipsychotic properties without overoccupying the receptor [99, 100]. In addition, clozapine has high affinity for 5HT2A,
Muscarinic M1 and α2-adrenoceptors (for further review, see [101]), supporting
significant involvement of neurotransmitter systems beyond direct dopamine
activation that contribute to its effectiveness. There are additional adverse side
effects involved in treatment with clozapine, most notably, haematological
reactions, dose-related reduction in seizure threshold, myocarditis and cardiomyopathy [102]. These risk factors require close monitoring, limiting the practical
utility of administering clozapine in treatment-resistant or chronically ill patients.
While antipsychotics show some efficacy in reducing psychotic symptoms
and preventing relapse in schizophrenia [91, 103], they have modest effects in
treating negative symptoms and cognitive deficits [104]. Recent large-scale clinical
trials also raise concern over the naturalistic efficacy of SGAs (compared to FGAs)
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Figure 1.4. Antipsychotic blockade of dopamine D2 receptors. First generation
antipsychotics have high affinity for dopamine D2 receptors, while second
generation antipsychotics have high potency but reduced specificity for
dopamine. Both acute and chronic blockade of D2 receptors contribute to the
unwanted side-effect profile of antipsychotics in the treatment of schizophrenia.
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when assessing real world outcomes. The Clinical Antipsychotic Trial of
Intervention Effectiveness (CATIE) [105] and the Cost Utility of the Latest
Antipsychotic Drugs in Schizophrenia Study (CUtLASS) [106] both failed to
demonstrate superior efficacy for either FGAs or SGAs on measures of treatment
discontinuation, improved psychotic symptoms, or increased quality of life. In a
meta-analysis examining the efficacy of fifteen different antipsychotics, only small
effects sizes were observed for amisulpride, olanzapine, and risperidone, all of
which were developed in the first series of SGAs [107].

Glutamatergic Treatments
The challenge for current pharmacological research is to address the underrecognised and treatment refractoriness of core negative symptoms and cognitive
deficits, and to optimise conditions for pharmaceutical benefit. A glutamatergic
model postulates hypofunction of prefrontal NMDArs that lead to reduced
excitatory networks and alterations in brain structure, function and downstream
neurotransmitter pathways [55, 108-110]. Direct activation of glutamatergic
receptors leads to neuronal cell death and is not a feasible option to manage the
hypofunctional NMDAr state of schizophrenia. Alternatively, activation of the
glycine modulatory site is one proposed mechanism of increasing glutamatergic
neurotransmission (Figure 1.5). In animal models of schizophrenia, glycine
reduced PCP-mediated psychotic symptoms [111, 112]. The same authors report
glycine increased NMDAr-mediated inhibition of dopamine release in the striatum
[113, 114], while glycyldodecylamide (GDA), a glycine type-1 reuptake inhibitor
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Figure 1.5. Glycine binding on N-methyl-D-aspartate receptors. Directly activating the glutamate binding site on N-methyl-D-aspartate
receptors (NMDArs) may lead to neuronal cell death or excitotoxicity. One alternative way to increase NMDAr function in schizophrenia is to
activate the glycine modulatory site. Novel therapeutic targets aim to increase synaptic glycine concentrations to rectify the hypofunctional
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(GT1-RI) stimulated NMDAr-mediated GABA release in the same region [114].
NMDAr agonists such as glycine [115-117] and D-serine [118, 119], as well
as the glutathione precursor N-acetyl-cysteine (NAC) [120], have demonstrated
improved clinical symptoms in patients on stable antipsychotic medication,
although some studies have failed to replicate these findings (for further review,
see [121]). While high-dose glycine has shown to improve negative symptoms
[117, 122, 123] and cognitive deficits [124] in treatment-resistant patients,
increasing synaptic glycine concentration under clozapine may saturate the
glycine modulatory site and initiate increased negative symptoms; glycine may
downregulate NMDAr activity [125] and D-cycloserine may displace fully occupied
sites [126].
Proof of concept studies administering GT1-RIs have shown promising
results for improving positive and negative symptoms [127]. However, a recent
phase-III clinical trial failed to support any benefit of the GT1-RI bitopertin when
compared to placebo [128], raising doubts as to the benefit of increasing synaptic
glycine concentration in schizophrenia. An editorial by Beck and colleagues [2]
raises concern of secondary negative symptoms inflating a placebo effect,
particularly in chronic patients. The authors further suggest the need for
stratifying biological dysfunction in clinical trials and the need for biological
markers to further inform mechanisms of treatment efficacy. Such markers may
help clarify inconsistent reports on therapeutic outcomes following increased
synaptic glycine concentration in schizophrenia.
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Cannabis Use in Schizophrenia
Substance use disorder is highly prevalent in schizophrenia, with approximately
50% of substance use in patients compared to 16% in the general population [129].
Notably, cannabis use is significantly higher in schizophrenia [130, 131] and in
individuals with a psychotic illness more generally [132]. A meta-analysis
estimated the prevalence of a cannabis use disorder in schizophrenia, indicating
clinically significant distress or impairment [11], for current use at 16% and
lifetime use at 27.1% [133]. In the Australian and New Zealand Clinical Practice
Guidelines cannabis is identified as the most serious comorbidity in schizophrenia
due to its widespread use [134]. Cannabis has been reported to worsen outcomes
in schizophrenia patients by enhancing cognitive deficits and psychotic symptoms
and increases the risk of relapse [135-137]. Chronic cannabis users, without
psychiatric history, also exhibit many cognitive phenotypes that are proposed
vulnerability markers of schizophrenia [138].

1.7.1 Structural and Functional Alterations
Disruption of normal endocannabinoid functioning may lead to alterations in brain
networks important for neuronal and cognitive development [139]. Cognitive
deficits in heavy and long-term cannabis users are thought to be mediated by
alterations in the hippocampus, prefrontal cortex and cerebellum [140]. These
regions are critically involved in memory and higher order cognitive processing
and are dense with cannabinoid receptors [141, 142]. The most commonly
reduced functions following acute and chronic cannabis exposure are attention

22

Chapter One

and verbal learning and memory, with some evidence of ongoing impairment after
prolonged cessation of use (for further review, see [143]). These findings are
supported by animal models reporting learning and memory impairment after
acute and chronic cannabinoid administration [144, 145].
Similarities in structural and functional deficits between cannabis users
and schizophrenia patients suggest a common underlying pathology [138].
Reduced hippocampal volume in cannabis users has been associated with
cumulative exposure to cannabis and increased development of subclinical
psychotic symptoms, where hippocampal reductions were of similar magnitude to
that observed in schizophrenia [146]. Molecular and electrophysiological
techniques have been used to demonstrate cannabinoid type-I (CB1) receptor
mediation of Δ9-Tetrahydrocannabinol (Δ9THC) induced reductions in long-term
potentiation [147]. In this study, Δ9THC was shown to down-regulate
glutamatergic receptor subunits in mice and induce their endocytosis via CB1
receptors. Repeated exposure to cannabis has also been shown to suppress longterm potentiation in the CA1 region of the hippocampus [148, 149]. These findings
suggest a complex interaction between endocannabinoid and glutamatergic
neurotransmitter function that is adversely affected by repeated Δ9THC exposure.

1.7.2 Endogenous Cannabinoids
Endocannabinoids and their receptors modulate physiological functioning in a
range of neuronal networking systems within the brain [150] and play an
important role in behavioural processes such as locomotion, anxiety, learning and
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memory [151]. The two main cannabinoid receptors, CB1 and cannabinoid type-II
(CB2), belong to the family of G-protein coupled receptors. CB1 receptors are
expressed in the central nervous system (CNS), with highest concentrations in the
basal ganglia, hippocampus, and prefrontal and anterior cingulate cortex, while
CB2 receptors are mainly found in the immune cells and peripheral tissues [152].
Endocannabinoids are lipid transmitters that serve as natural ligands for
cannabinoid

receptors,

with

the

main

endocannabinoids

being

arachidonoylethanolamide (anandamide or AEA) and 2-arachidonoylglycerol (2AG). Endocannabinoid synthesis is located on membrane phospholipids in
response to postsynaptic intracellular CA2+, a process that may be aided by postsynaptic G-protein couple receptor activation.
Cannabinoid receptors mediate the inhibition of neurotransmitter release
throughout the central nervous system, including glutamate, dopamine and GABA
[153-155]. Depolarised induced suppression of excitation (DSE), the process of
inhibiting neurotransmitter release from glutamatergic neurons, occurs when CB1
receptors inhibit voltage-gated Ca2+ channels and K+ conductance [156]. DSE
occurs when 2-AG is released from CA1 pyramidal neurons during depolarisation
and act in a retrograde manner to activate CB1 receptors on Schaffer collateral
axon terminals [156]. CB1 receptors regulate activation of NMDArs, via coupling of
histidine triadnucleotide-binding protein 1 (HINT-1) [157], to prevent further CA2+
influx and therefore protect against neuronal excitotoxicity. As NMDArs become
highly activated, cannabinoids are recruited on demand to co-internalise the NR1
subunit of the receptor, negatively controlling NMDAr function via retrograde
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synaptic messaging [158].

1.7.3 Exogenous Cannabinoids
The endocannabinoid system is the binding site of exogenous cannabinoids, such
as Δ9-THC, which disrupt normal endocannabinoid regulation of neuronal
excitability within the brain [159]. Δ9THC is the main psychotropic constituent in
cannabis [160] and is a partial agonist at CB1 and CB2 receptors. CB1 receptors
located on glutamatergic neurons appear to be activated at lower concentrations
of Δ9THC compared to those on GABAergic neurons, suggesting a bell-shaped
dose-response excitatory curve [161]. Cannabidiol (CBD), also an exogenous
cannabinoid found in cannabis plant matter and partial agonist at CB1 and CB2
receptors, has purported anxiolytic and antipsychotic properties (for further
review, see [162]). Although CBD has low affinity at CB1 receptors, it has negative
allosteric modulator properties [163, 164] that reduce the ability of CB1 agonists,
such as Δ9THC, to bind to the receptor.
Increased activation of CB1 receptors has been shown to induce psychotic
states in vulnerable individuals [165, 166] and worsen symptoms in schizophrenia
patients [135]. Alterations in endocannabinoid regulation of glutamatergic
function, whereby CB1 receptors restrict NMDAr activation, may lead to prolonged
states of NMDAr hypofunction or downregulation of NMDArs, conditions that are
synonymous with the pathophysiology of schizophrenia (see section 1.3). Overactivation of pre-synaptic CB1 receptors may inhibit glutamate release in the
synaptic cleft, while post-synaptic CB1 receptors may alter NMDAr signalling
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pathways. Prolonged states of reduced NMDAr signalling may lead to alterations
in downstream neurotransmitter functioning, such as dopamine [167], providing
a mechanism for which repeated exposure to Δ9THC may precipitate psychotic
symptoms in vulnerable individuals.
It is unclear whether smoked cannabis alters CB1-NMDAr associations to
differentially affect the neuronal response to NMDAr-mediated treatments in
schizophrenia. The efficacy of increasing synaptic glycine concentration may be
reduced under conditions of elevated CB1-mediated inhibition of NMDAr
activation. While most of the pharmacological action of exogenous cannabinoids
is reported for CB1 receptors, Δ9THC and CBD may also alter glutamatergic and
GABAergic function via CB1-independent mechanisms (for review of additional
molecular targets not discussed here, see [168]). In neurons located in the ventral
tegmental area in mice, Δ9THC potentiates glycine receptor-mediated currents via
allosteric mechanisms in a dose-response manner [161]. These findings suggest
exogenous

cannabinoids

alter

neural

activation

and

downstream

neurotransmitter release in brain networks implicated in the pathophysiology of
core schizophrenia phenotypes (see section 1.3.1). Of particular relevance to the
current thesis is that different combinations of Δ9THC and CBD potency found in
cannabis plant matter [169], as well as evidence for their dose-dependent
outcomes (for further review, see [170]), may lead to differential effects of
cannabis on NMDArs and associated signalling pathways. There is need to further
clarify the effects of repeated cannabis use on vulnerability markers indexing
hypofunctional NMDAr activity in schizophrenia.
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Chapter Summary
While neuroscience has advanced our understanding of the biological
underpinnings of schizophrenia, there remains vast heterogeneity in response to
pharmacological treatments. A dopaminergic hypothesis provides a clear link to
antipsychotics targeting dopamine D2 receptor function.

However, a

glutamatergic hypothesis proposes preliminary dysregulation that accommodates
core refractory symptoms and cognitive deficits, specifying NMDArs as a logical
neuronal target for pharmacological intervention. The shift from a narrowly
defined dopamine hypothesis, to the refinement of broader neurobiological
models such as glutamate, has guided the development of alternative treatments
which are progressing through preclinical and clinical phases of testing. A
challenge for current neuropsychopharmacological research is to clarify
mechanisms of improved clinical outcomes and to increase the specificity and
sensitivity of diagnostic and treatment tools [171].
Increasing synaptic glycine concentration is one potential method to
rectify the hypofunctional NMDAr state in schizophrenia. Phase-II clinical trials
have found some evidence that this method improves positive and negative
symptoms [119, 127, 172, 173], while other studies have failed to replicate these
findings [128]; this raises some doubt as to the benefit of increasing post-synaptic
glycine concentrations in schizophrenia. The endocannabinoid system plays a key
role in regulating NMDAr activation and disruption of this regulatory mechanism,
such as that following regular cannabis use, may alter neurotransmitter
functioning in target pathways of NMDAr-mediated treatments. Clarifying the role
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of the endocannabinoid system (both related and unrelated to regular cannabis
use) on cortical and subcortical networks deficient in schizophrenia, may help to
inform mechanisms of core refractory phenotypes. The application of biomarkers
in glutamatergic-mediated pharmacotherapy trials may be a useful means of
informing the relationship between functional target engagement and improved
clinical outcomes. Further, they may help clarify inconsistent reports on the
benefits of increasing synaptic glycine concentration to improve clinical symptoms
in schizophrenia.
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Auditory Mismatch
Negativity

Mismatch Negativity

2.1

Chapter Introduction

In pharmacotherapy trials, biomarkers aim to clarify the relationship between
neuronal occupancy and expected therapeutic benefits. Absence of such
measures in preclinical trials can make it difficult to interpret inconsistent reports
on clinical outcomes, as is the case for treatments that aim to increase synaptic
glycine concentration in schizophrenia. The primary auditory pathway is one
neurobiological system that allows unique insight into the integrity of excitatory
neurotransmitter functioning within the brain. Mismatch Negativity (MMN) is a
measure of auditory change detection and is a potential biomarker to index Nmethyl-D-aspartate receptor (NMDAr) hypofunction in schizophrenia. There is
need to determine the nature of the relationship between MMN and NMDAr
function, in order to inform the utility of MMN to index neuronal integrity in brain
regions and pathways underlying core refractory symptoms.
The following chapter defines MMN as an event-related potential indexing
deviance detection and discusses the pharmacology of its generation, with
particular focus on neuronal networks and brain regions relevant to the
pathophysiology of schizophrenia. Discussions on the hierarchical structure of the
primary auditory pathway and networks involved in processing frequency and
duration sound features, provide a framework to discuss the contribution of
excitatory and inhibitory networks involved in MMN generation. This chapter
reviews MMN findings within schizophrenia and proposes MMN as a potential
biomarker to stratify NMDAr dysfunction within the disorder. Further, this chapter
concludes that changes in MMN may be useful to index alterations in NMDAr
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function following neuronal target engagement of pharmacological treatments.

2.2

Mismatch Negativity Defined

MMN indexes the brain’s pre-attentive ability to detect stimulus change in sensory
memory. Auditory MMN is a negative deflection of the event-related potential
(ERP), elicited above the threshold of discrimination between a deviant stimulus
and a pattern of sounds forming a sensory memory trace [174, 175]. Deviant
stimuli may vary from the memory trace, also referred to as standards, in differing
complexity, such as change in spectral, temporal, or higher order features [176,
177] (higher order constructs such as phonetic structure, sequence pattern and
stimulus omission are not discussed here). Typically, MMN is calculated by
subtracting the ERP to standards from the ERP to deviants, creating a difference
waveform (see section 2.2.1). The negative potential observed in the difference
waveform is thought to index additional excitatory processing required for
deviance detection. As MMN is a pre-attentive measure of attention and is
responsive to neurobiological change, it is a candidate biomarker for translational
clinical research.

Electroencephalographic Measurement
MMN is elicited approximately 100-200ms after the onset of a deviant stimulus
[178]. It is typically measured by recording ongoing spontaneous neuronal activity
via electroencephalograph (EEG) at frontal electrode sites, compared to a
relatively neutral reference electrode such as the nose or linked mastoids [179].
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The EEG recording at each electrode indexes the voltage signal of many neurons
working together across time-varying domains. The latency of the ERP indexes
both the degree of neural activity required to process the stimulus and ongoing
neural activity that is non-specific to the stimulus. In order to remove the nonspecific or irrelevant neural activity, multiple ERP trials to the same stimulus
presentation are averaged together. This method assumes that neural activity
generated in response to the stimulus will be most prominent in the averaged
waveform due to its consistent temporal presentation across trials, while the nonspecific activity is ‘averaged out’ along the temporal domain of the ERP recording.

Oddball Paradigm
Typically, much research has utilised an auditory oddball paradigm to measure
MMN, whereby deviant tones are presented intermittently within a background
of identical standard tones (Figure 2.1). The number of standard tones is
presented at differing train lengths to allow the deviant stimulus to be presented
at unexpected time intervals and of an unknown probability. The deviant tone may
be characterised by, but not limited to, changes in duration, frequency, intensity,
or spatial location of a sound. The average response to all standard tones is
subtracted (separately) from the averaged response to each type of deviant tone,
creating a difference MMN waveform for each deviant type.

Roving Paradigm
In a roving MMN paradigm, each stimulus type functions as both a standard and
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deviant throughout the MMN sequence and is randomly repeated in blocks of
differing train lengths. The first stimulus in each block functions as a deviant
stimulus, due to the relative change in sound properties from the preceding block
(Figure 2.2a). Rather than reverting back to the same standard stimulus, as is
typical in an oddball paradigm, the roving design continues to repeat the ‘deviant’.
After two-to-three presentations, the deviant stimulus is processed as a new
series of standards (Figure 2.2b). Therefore, the relative presentation order of a
stimulus defines it as a deviant or standard (Figure 2.2c). MMN waveforms are
calculated for each stimulus type separately, in order to control for sound
properties. This is achieved by subtracting the averaged standard ERP from the
averaged deviant ERP across stimuli with identical sound features (Figure 2.2c).

2.3

Mismatch Negativity Generators

MMN has traditionally been defined as an index of functioning in auditory cortical
networks required for deviance detection. The most consistently reported
generators of MMN include the temporal and frontal cortices [176, 180, 181].
Functional magnetic resonance imaging (fMRI) has shown increased activation in
the superior temporal gyrus of the auditory cortex (AC) in response to deviant
tones [182]. The AC is proposed to detect sound features and establish a memory
trace to which incoming stimuli are compared [174]. Cerebral blood flow, EEG and
scalp current density analyses have provided evidence for an additional frontal
generator in the inferior frontal gyrus (for further review, see [183]), with evidence
to suggest that duration deviants predominately activate the left inferior frontal
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Figure 2.1. Mismatch negativity oddball paradigm. In an oddball mismatch negativity paradigm, a series of standard stimuli [blue] are
presented at differing train lengths to establish a memory trace in auditory sensory memory. Deviant stimuli [red] (i.e. deviating from the
standard in frequency, intensity or duration), are interspersed within the train of standards at unexpected time intervals.

Memory Trace
a)

Deviant
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Figure 2.2. Mismatch negativity roving paradigm. In a roving mismatch negativity (MMN) paradigm, different stimuli are presented in
blocks of varying train length: a) The first tone in the new block functions as a deviant (red deviant), due to the change in sound properties
relative to the preceding memory trace (blue memory trace); b) The deviant tone is repeated in order to establish a new memory trace of
identical sound features (red memory trace); c) The MMN difference waveform is calculated for each stimulus type separately, whereby the
event-related potential (ERP) of the standards (for example, the average of all green memory traces) is subtracted from the ERP of
corresponding deviant stimuli (for example, the average of all green deviants).
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gyrus [184], while frequency deviants activate the right inferior frontal gyrus [182,
184]. Frontal activation is related to an involuntary switch in attention that is
required for higher-level deviance detection when comparing a stimulus to an
established memory trace [184-186].

2.4

Stimulus-Specific Adaptation

The generation of MMN is thought to result from a series of deviance detection
processes occurring in both subcortical and cortical structures of the auditory
pathway. Stimulus-specific adaptation (SSA) is a form of short-term plasticity in
response to a repeated stimulus. When the same stimulus is repeated, such as
standard tones in an oddball paradigm (see section 2.3.1), the neuronal activation
in response to the stimulus is reduced. Following the presentation of a deviant
stimulus, the firing rate of the same neurons are significantly increased, releasing
the suppression of neuronal firing imposed on the repeated stimulus [187]. This
finding supports the separation of the SSA response from an independent model
of neuronal fatigue. SSA in response to deviant stimuli are well developed in
regions of the midbrain [188], suggesting that SSA contributes proportionally to
deviance detection processes generated higher in the auditory pathway, including
MMN. While SSA contributes to deviance detection via bottom-up processing of
sound features, corticofugal projections from the AC help to modulate the firing
rate of neurons in midbrain structures [189] (corticofugal projections supporting
SSA are discussed further in section 2.6).

36

Chapter Two

2.5

Prediction Error Encoding

The magnitude of the MMN is dependent on the strength of the standard pattern
in echoic memory, implicating an important role of synaptic plasticity in MMN
generation. The detection of a deviant stimulus requires on-line modification of
the established memory trace [190], such that the brain receives bottom–up
thalamic inputs which inform current stimulus properties and allow the brain to
adjust top–down predictions [191, 192]. A model of prediction error defines MMN
as the difference between these thalamic inputs and NMDAr spike timing of a
dependent synaptic plasticity discharge, which occurs when information is fedback to predictive neurons. This model suggests reduced efficiency in having learnt
the regularity of the predictive rule (the standard memory trace), or impairment
in detecting or communicating the response to an unexpected deviant stimulus.
In the latter case, MMN is considered a prediction error signal of the acoustic
environment [193, 194].

2.6

Auditory Processing Hierarchy

Processing of auditory sound features begins in the cochlear nucleus. Neuronal
signals ascend through the inferior colliculus (IC) to the medial geniculate body
(MGB; part of the auditory thalamus). The cytoarchitecture of the MGB suggests
that spectral and temporal properties are deconstructed, prior to being processed
in core areas of the primary (AI) and secondary (AII) AC [195]. The frontal cortex
tracks the violation of expected sounds by comparing change in stimulus features,
generating low frequency activity in response to a prediction error [196].
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The descending cortico-thalamic and cortico-collicular pathways assist in
neuronal adaptation and deviance detection at the level of subcortical structures
[189]. Descending projections to the MGB and IC primarily extend from layer V
and VI of the AI [197-199]. The MGB has a high ratio (10:1) of corticofugal
projections compared to the corresponding ascending pathways [200, 201]. These
projections demonstrate strong stimulus-specific adaptation, indexing a gain
control mechanism of the AC to MGB neurons. Corticofugal projections update
sensory representation of sounds, via synaptic depression, which is then projected
back to higher order cortical areas [202, 203]. Sounds features are then integrated
in the belt and parabelt areas surrounding the AI and AII, before projecting to the
frontal and parietal cortices for higher order processing required for deviance
detection [195].

2.6.1 Frequency Sound Processing
Tonotopic maps are the spatial arrangement of different laminae or bands
sensitive to differing sound frequencies. These maps ascend through the auditory
pathway in a bottom-up fashion, allowing the processing of sound frequency to
be communicated directly to corresponding bands in the next level of the
ascending auditory pathway [204]. Projections extending from the central nucleus
of the IC, to the ventral division of the medial geniculate body (MGBv) and AI, form
the leminiscal pathway of the auditory system. Neurons in the leminiscal pathway
are of short latency, sharp tuning curve, and have a consistent neuronal response
to differing sound frequencies [205]. There is evidence to suggest this tonotopic
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organisation in the leminiscal pathway also extends to belt areas of the AC [206208].

2.6.2 Duration Sound Processing
Within the brainstem, neurons are non-selective to the duration of a sound,
having a sustained response to the duration of all auditory stimuli. Within the IC,
further along the ascending auditory pathway, duration-tuned neurons have a
neurophysiological response characterised by specific stimulus durations. These
duration-tuned neurons have also been reported in areas of the auditory thalamus
and AC in mammals [195, 209]. The selective activation of duration-tuned neurons
occurs via excitatory inputs corresponding to the onset and offset of a stimulus,
while temporally offset inhibitory inputs supress the excitatory response occurring
at neurons of non-corresponding durations [195, 210]. Projections from the IC to
the medial (MGBm) and dorsal (MGBd) divisions of the MGB and belt areas of the
AC are less tonotopically organised, forming the non-leminiscal pathway of the
auditory system. In the MGBd, neurons are typically of broad tuning curve, while
the MGBm appears to have both broad and narrow-tuned neurons to allow more
accurate discrimination between different sound durations [205]. The leminiscal
and non-leminiscal pathways are not mutually exclusive, rather, temporal and
spectral processing occurs parallel to allow complex integration of differing sound
properties. Corticofugal projections from the AC descend primarily to the nonleminiscal subcortical structures of the MGB and IC [211]. The processing of
duration sound features requires the complex decomposition of the sound and
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connectivity across a range of ascending and descending neuronal projections
between subcortical and cortical regions.

2.7

Pharmacology of Mismatch Negativity

The pharmacological underpinnings of MMN have been investigated by
modulating different neurotransmitter system functioning [212]. Auditory sensory
memory, like other areas of working memory, involves a complex interaction of
excitatory and inhibitory processes. The most robust and consistent
pharmacological modulation of MMN has been demonstrated by altering NMDAr
function (for further review, see [213, 214]). Minimal effects have been reported
following modulation of dopaminergic [215], serotonergic [214, 216, 217] and
gamma-aminobutyric acid (GABA) type A [218] receptor modulators. MMN
appears heavily dependent on glutamatergic function, the main excitatory
neurotransmitter system in the brain, and more specifically on excitatory
pyramidal neurons [87].

2.7.1 Glutamate
Several studies have reported MMN reductions in humans following acute
ketamine administration, an NMDAr antagonist, for both frequency and duration
deviants [214, 219-222]. Two studies failed to replicate these findings: Oranje and
colleagues [223] suggest that their negative findings may reflect low plasma level
of ketamine at 158ng/ml, compared to 426ng/ml reported in an earlier positive
study [221]; Roser and colleagues [224] also failed to find an effect of ketamine
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and reported similar low plasma levels (133.8±58.2ng/ml) comparable to previous
negative findings. Further support for a critical role of NMDAr function in
generating MMN comes from administration of other NMDAr antagonists
including Nitrous Oxide (N20) gas [199] and memantine [200]. At low doses,
memantine increased MMN amplitude, potentially due to the ability of
memantine to increase glycine affinity when administered at low doses [201].
Contrary to expectations that glycine would increase MMN amplitude, highdose glycine reduced duration MMN amplitude in healthy controls [225]. In that
study, participants were administered 0.8g/kg of glycine, the dose typically
reported for clinical benefits in schizophrenia. The observed reduction in MMN
amplitude may be indicative of a worsening in pre-attentive change detection in
individuals with intact glutamatergic function prior to glycine administration. This
interpretation is supported by animal models reporting cognitive impairment
beyond optimal levels of synaptic glycine concentration [226]. These findings
suggest a dose-dependent relationship between glycine and NMDAr function prior
to glycine administration, whereby glycine may increase MMN amplitude in those
with relatively low baseline NMDAr function, such as in schizophrenia, while
reducing MMN amplitude in those with normal baseline functioning. However, the
nature of this relationship has not been examined directly.

2.7.2 Dopamine
Modulating dopamine signalling has yielded a weak association with MMN
generation. Studies in healthy controls have shown no effect of bromide, a
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dopamine type-II (D2) receptor agonists, or pergolide, a dopamine receptor type-I
(D1) and D2 receptor agonist, on MMN amplitude [215, 227]. No changes in MMN
were observed following growth hormone response to apomorphine (nonselective dopamine agonist) or clonidine (an ą2 adrenergic agonist) [228],
providing indirect evidence that MMN generation is not dependant of
dopaminergic function. In addition, inhibiting the reuptake of dopamine and
norepinephrine under methylphenidate did not affect MMN [229]. Of three
studies that have investigated the effects of haloperidol, a dopamine D2 receptor
antagonist and antipsychotic treatment for schizophrenia (see section 1.5), two
studies reported no effects on MMN amplitude [230, 231]. Only one study
reported that haloperidol reduced MMN amplitude in healthy controls, in addition
to increasing other selective and non-selective components of the ERP [232].

2.7.3 Cannabinoid
Altered synaptic plasticity in regular cannabis users [148, 233] is thought to occur,
in part, due to cannabinoid type-1 (CB1) receptor-mediated downregulation of
NMDArs [147, 148]. An acute administration study of exogenous cannabinoids
found Δ9-Tetrahydrocannabinol (Δ9-THC) did not affect MMN amplitude in healthy
controls, while co-administration of Δ9-THC and cannabidiol (CBD) increased MMN
amplitude [234]. These effects of Δ9-THC have shown to be mediated by the
neuregulin 1 gene [235, 236], while in a separate study, the CB1 receptor agonist
rimonabant reduced MMN amplitude [237]. Roser and colleagues [237] reported
no group differences between cannabis users and controls overall for duration or
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frequency MMN, but long-term and heavy cannabis users showed smaller
frequency MMN amplitude at frontal sites when compared to shorter-term and
lighter cannabis users. Rentzsch and colleagues [238] reported attenuated
frequency MMN amplitude in abstinent users and while no differences were found
in that study between chronic cannabis users with and without schizophrenia,
both patient groups had smaller MMN amplitude compared to controls.
Interestingly, group differences in each of these studies were primarily
highlighted for the MMN component elicited by a frequency deviant; although
both studies included a duration deviant condition, neither study reported any
group differences for duration MMN. Pesa and colleagues [239] reported an
altered pattern of duration MMN in first-episode psychosis patients who used
cannabis, relative to patient nonusers. In that study, increased quantity and
frequency of recent cannabis use was associated with smaller duration MMN
amplitude. More recently (and since the publication of our findings in chapter
four), Impey and colleagues [240] reported reduced duration MMN amplitude in
nicotine naïve cannabis users. Together, these findings suggest that longer periods
of heavy cannabis use may reduce MMN amplitude. Given the prevalence of
cannabis use in patients within schizophrenia [133] and the effects of the
endocannabinoid system in regulating NMDAr function [217], further clarification
of the relationship between current regular cannabis use and MMN is required
(see section 1.7.2 for a review of endocannabinoid-mediated regulation of NMDAr
function).
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2.8

Mismatch Negativity in Schizophrenia

Reduced MMN amplitude in schizophrenia is a robust phenotype, with a metaanalysis of studies reporting a large mean effect size (Cohen’s d>1) [241]. An
earlier meta-analysis separately reported a large effect size for duration MMN
(d=1.01) and a medium effect size for frequency MMN (d=0.47) [242]. Smaller
MMN amplitude has been associated with impaired daily functioning [243] and
cognitive deficits [244]. Todd and colleagues [212] propose that MMN is more
likely to index stable features of schizophrenia, however the relationship between
MMN and discrete clinical symptoms or functional outcomes has not been
consistently reported (for further review, see [89]). Clarifying the nature of the
relationship between MMN, NMDAr function and discrete phenotypes in
schizophrenia, may inform mechanisms of core clinical features and changes in
neurobiological function underlying clinical treatment efficacy.
As is the case in MMN more broadly, the degree of MMN generation in
schizophrenia is influenced by stimulus features, such as the degree of perceptual
discrimination between standards and deviants and the predictability of a deviant
presented within a standard memory trace [245]. Greater differentiation between
a deviant stimulus and the memory trace typically elicits a larger MMN response
[174, 192]. What is thought to be deficient in schizophrenia is the ability to
produce larger MMN amplitudes with increasing stimulus deviance, as the MMN
amplitude appears to plateau earlier compared to controls along a continuum of
increasing stimulus discrepancy [246]. Therefore, greater differences between
patients and controls become more prominent with increasing differences in
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stimulus features.
Reduced MMN to duration deviants is a robust finding in patients with
early onset schizophrenia and has been shown to be impaired in the prodromal
phase of illness and those at risk of developing psychosis [247-249]. Longitudinal
evidence provides further support for MMN as a translational biomarker, with
smaller MMN amplitudes predicting conversion to schizophrenia [247, 248]. In
contrast, attenuated frequency MMN amplitude has been associated primarily
with chronic schizophrenia illness [250]. These findings of frequency MMN deficits
are thought to relate to the tonotopic organisation of the AC and alterations in
plasticity with disease progression [250-253]. Smaller MMN generation in
schizophrenia is unlikely due solely to the generation of MMN in the frontal cortex,
as MEG studies have also demonstrated deficient MMN generation in patients and
this measure is insensitive to frontal cortical activation [254]. While differences for
duration versus frequency MMN do not offer clear discrimination of
neurotransmitter functioning involved in the stage or severity of illness [255],
MMN overall appears sensitive to changes in NMDA neurotransmitter function
throughout the disorder.

2.8.1 Antipsychotic Medication
The use of antipsychotic medications does not significantly impact MMN
amplitude in schizophrenia patients. Both clozapine and haloperidol have thus far
failed to consistently modulate MMN amplitude, while clozapine consistently
increased P300 in the same studies [256-258]. Once MMN deficits are observed,
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they tend to persistent despite ongoing antipsychotic medication. This is contrary
to the pattern of sensory gating deficits, which are more reliant on dopaminergic
function and typically resolve following reduced psychotic symptoms treated with
antipsychotics [259]. These findings indicate that MMN is related to
neurochemical imbalances independent of dopaminergic functioning and may be
a useful tool for examining pharmacological underpinnings of the disorder in
relation to glutamatergic models [260].

2.8.2 Glutamatergic Treatments
A 60-day trial of N-acetyl-cysteine (NAC), a glutathione precursor, significantly
increased MMN in schizophrenia, without affecting the P300 component. It is
unclear in this study whether the effect of increased MMN amplitude is from
cysteine properties enhancing NMDAr function, or other mechanisms such as
redox-sensitive transcription factors (or both) [261]. Magnetic resonance
spectroscopy findings have reported that smaller duration MMN amplitude is
associated with reduced glutathione levels in the posterior medial prefrontal
cortex and further associated with increased negative symptoms in schizophrenia
[262]. Using structural equation modelling, MMN has also been reported as an
intermediary biomarker between glutamate dysfunction and verbal learning
memory deficits in patients [263]. This study found smaller duration MMN was
associated with reduced glutamate, GABA and glutamate-to-glutamine ratios in
the medial prefrontal and anterior cingulate regions in schizophrenia. Together,
these findings support the role of NMDAr hypofunction in the generation of
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smaller MMN amplitudes in schizophrenia and support the utility of MMN as a
biomarker to index change in NMDAr function following treatment administration.

2.9

Chapter Summary

MMN may be a useful biomarker of functional target engagement to help clarify
the relationship between NMDAr-mediated treatments and therapeutic efficacy
in schizophrenia. However, few studies have investigated the pharmacology of
altered MMN in schizophrenia directly, particularly following administration of
NMDAr-mediated treatments. Findings from Leung and colleagues [225] suggest
that high-doses of glycine (0.8g/kg) may reduce (rather than increase) MMN in
those with intact baseline NMDAr function, supporting the presence of an
Inverted-U dose-response relationship between synaptic glycine concentration
and cognitive performance in humans. Determining the nature of this relationship
is particularly important due to the heterogeneity of NMDAr dysfunction within
schizophrenia [53-55].
Given the regulatory mechanism of endocannabinoids on NMDAr
activation via pre- and post-synaptic mechanisms (see section 1.7.2), it is
reasonable to assume that cannabis exposure reduces MMN following regular use,
and may prevent the efficacy of increased synaptic glycine concentration to
improve NMDAr function. Early findings suggest that cannabis does not alter the
observed MMN deficit in schizophrenia [238], while prolonged and heavier
cannabis use in healthy controls [237], and more frequent and heavier use in first
episode psychosis [239], has been associated with smaller MMN amplitude. It may
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be that in healthy controls the effects of cannabis use are more pronounced, while
a floor effect of reduced MMN in patients restricts observation of further
impairment in MMN following exposure to cannabis. Such findings may confound
the utility of MMN to index neurobiological function related to the
pathophysiology of schizophrenia and may modulate the neuronal response to
NMDAr-mediated treatments.
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Outline of the Current
Thesis

Thesis Outline

3.1

Literature Summary

Increasing synaptic glycine concentration may assist in treating core refractory
symptoms in schizophrenia. However, inconsistent reports of therapeutic efficacy
have raised doubt as to the benefit of such treatments. Endocannabinoidmediated alterations in NMDAr excitability may modulate neuronal functioning in
target pathways of NMDAr-mediated treatments. Cannabinoid receptor type-I
(CB1) agonism, following repeated cannabis use, may lead to increased inhibition
of NMDArs and potentially reduce the clinical efficacy of increasing synaptic
glycine concentration in schizophrenia. Peripheral markers, such as plasma glycine
or Δ9-Tetrahydrocannabinol (Δ9-THC) concentrations, are limited in informing
neuronal functioning within the brain. Utilising biomarkers that index
neurotransmitter functioning in brain networks involved in the pathophysiology
of schizophrenia may help clarify the neurobiological relationship between neural
target

engagement

and therapeutic efficacy

following

pharmaceutical

intervention.
The primary auditory pathway is one neurobiological system which may
inform changes in neuronal functioning following administration of NMDArmediated treatments. Specifically, MMN may inform the neuronal integrity of
NMDArs following increased synaptic glycine concentration in schizophrenia. Few
studies have examined the direct pharmacological modulation of MMN using
NMDAr agonists in patients, while early evidence suggests that the relationship
between synaptic glycine concentration and NMDAr function is characterised by
an Inverted-U dose-response relationship. Therefore, the therapeutic efficacy of
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glycine-mediated treatments may depend on NMDAr function prior to treatment
administration. MMN may be a useful biomarker to stratify neurobiological
dysfunction of NMDArs in schizophrenia and index mechanisms of improved
clinical symptoms following neuronal target engagement of NMDAr-mediated
treatments.

3.2

Thesis Aims

The aim of the current thesis is to determine the nature of the relationship
between MMN and NMDAr function, in order to inform the utility of MMN as a
biomarker to stratify NMDAr dysfunction and index neuronal target engagement
of NMDAr-mediated treatments in schizophrenia. To achieve this aim, we
investigated the relationship between MMN and altered NMDAr function in three
independent studies, following: prolonged periods of regular cannabis use in
otherwise healthy individuals; acute and chronic administration of glycine in
schizophrenia patients; and a glycine dose-dependence trial in healthy controls.
There was no participant overlap between studies described in this thesis.
In chapter four we investigate the effects of regular cannabis use on MMN
by comparing current regular cannabis users against a sample of healthy age- and
gender-matched nonuser controls. Given the role of the endocannabinoid system
in regulating NMDAr function and glutamate release within the brain, it is
important to know whether regular cannabis use alters neuronal functioning in
target pathways of novel NMDAr-mediated treatments. Based on models of
NMDAr-mediated structural and cognitive dysfunction following repeated
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exposure to exogenous cannabinoids, we hypothesise that individuals with
prolonged and heavy cannabis use will have smaller MMN amplitudes compared
to matched controls.
In chapter five we investigate whether an acute dose and repeated
administration of glycine increases MMN amplitude in schizophrenia patients.
Further, we investigate whether baseline and changes (from baseline to postglycine) in MMN amplitude are associated with change in clinical symptoms
following 6-weeks of adjunct glycine treatment. Given inconsistent reporting of
therapeutic benefits following NMDAr-mediated treatments in schizophrenia,
there is need to establish biomarkers, such as MMN, to index neuronal target
engagement and further inform the mechanisms of therapeutic efficacy. We
hypothesise that acute glycine (0.2g/kg) and adjunct glycine treatment
(0.6g/kg/day; 6-weeks) will increase MMN amplitude in schizophrenia. We also
hypothesise that smaller baseline MMN amplitude (indicating poorer NMDAr
functioning) will be associated with greater improvements in clinical symptoms
following adjunct glycine treatment.
In chapter six we investigate the dose-response relationship between glycine
and MMN in an independent sample of healthy controls. Following the outcomes
of chapter five and further evidence suggesting glycine may only exert therapeutic
benefits within an optimal range of synaptic glycine concentration, we compare
the effects of placebo and three different glycine doses (0.2g/kg; 0.4g/kg; 0.8g/kg)
on MMN generation. We hypothesise an Inverted-U dose-response relationship
between increasing glycine dose and MMN amplitude. In chapter seven the
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findings of previous chapters are summarised and discussed, as well as their
limitations and directions for future research.
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Chapter Seven
Summary and Discussion

Discussion

7.1

Scope of the Thesis

The aim of the current thesis was to determine the nature of the relationship
between mismatch negativity (MMN) and alterations in N-methyl-D-aspartate
receptor (NMDAr) function. Understanding this relationship is important as it
informs the utility of MMN to stratify NMDAr dysfunction in schizophrenia and to
index functional target engagement following NMDAr-mediated treatments. In
order to achieve this overarching aim of the thesis, three independent empirical
studies were performed: The first study (chapter four) aimed to determine
whether MMN is smaller in regular cannabis users compared to controls; the
second study (chapter five) aimed to determine the effects of acute and repeated
glycine administration on MMN in chronic schizophrenia patients and its relation
to treatment outcomes; the third study (chapter six) aimed to determine the
nature of the dose-response relationship between glycine and MMN in healthy
controls.
The empirical studies in this thesis were supported by two separately
funded research schemes. Chapter four, examining MMN in cannabis users, was
part of a project scheme investigating vulnerability markers in the association
between cannabis use and schizophrenia. Chapters five and six, examining the
effects of glycine in schizophrenia and in healthy controls, were part of a scheme
investigating the efficacy of glycine as a therapeutic adjunct treatment in chronic
schizophrenia patients. While these studies were part of a broader series of
projects, they are complementary in clarifying the relationship between NMDAr
function and MMN generation.
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7.2

Summary of Findings

In chapter four, we examined duration and frequency MMN processing in a
sample of forty-two regular cannabis users, compared to forty-four age- and
gender-matched non-user controls. Within this sample, we then examined MMN
in shorter- and longer-term cannabis users relative to their matched control
counterparts. Frequency MMN amplitude was smaller in the overall sample of
cannabis users, with this finding evident in both short- and long-term user groups.
Smaller duration MMN amplitude was more pronounced in long-term users
compared to controls and shorter-term users, and was associated with more
prolonged and heavier cannabis use, particularly daily use, across the entire
sample of regular users.
In chapter five, we examined the effects of acute glycine administration
(0.2g/kg) and chronic glycine treatment (increased to 0.6g/kg) as an adjunct to
ongoing antipsychotic medication in chronic schizophrenia. In a sample of twentytwo schizophrenia (or schizoaffective disorder) out-patients we compared the
effects of glycine to that of placebo, utilising a randomised, double-blind,
between-groups design. In this study, duration MMN amplitude at baseline was
smaller in schizophrenia compared to age- and gender-matched controls. Acute
administration of glycine increased duration MMN amplitude compared to
placebo, while no between-group differences in MMN were found after 6-weeks
of repeated glycine administration. Smaller duration MMN amplitude at baseline
was associated with greater negative symptoms assessed using the Positive and
Negative Syndrome Scale (PANSS) and predicted a trend-level improvement in
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negative symptoms following 6-weeks of adjunct glycine treatment (improvement
defined as significantly reduced symptom scores from baseline to post-6-week
treatment). No changes in negative symptoms were found following placebo.
In chapter six, we examined the dose-response relationship between
glycine and MMN in an independent sample of twenty healthy controls. In this
study, we report a quadratic relationship between increasing glycine dose and
change in MMN amplitude, providing evidence for an Inverted-U dose-response
relationship following acute glycine administration. High-dose glycine (0.8g/kg)
reduced MMN amplitude compared to low-dose (0.2g/kg) and medium-dose
(0.4g/kg), while low-dose glycine increased MMN amplitude (at trend level)
compared to placebo. Further, baseline MMN amplitude was linearly associated
changes in MMN (from baseline to post-drug) following glycine administration,
whereby larger baseline amplitudes were associated with reduced MMN and
smaller baseline amplitudes were associated with increased MMN.

7.3

General Discussion

This thesis reports findings of smaller MMN amplitudes in regular cannabis users
without psychiatric history, suggesting that regular use alters the sensitivity of
MMN to index NMDAr functioning directly related to the pathophysiology of core
schizophrenia phenotypes. Although the effects of regular cannabis use were not
examined in schizophrenia patients, chapter four aimed to determine the nature
of the relationship between regular cannabis exposure and MMN in otherwise
healthy subjects. These findings were used to infer the effects of regular cannabis
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use in altering endocannabinoid-mediated regulation of NMDAr excitability.
Smaller MMN amplitudes in regular cannabis users (chapter four) support
previous studies reporting cannabinoid type-I (CB1) receptor-mediated inhibition
of NMDArs [156-158]. These findings suggest that prolonged cannabis use disrupts
CB1-NMDAr regulatory mechanisms, thereby reducing NMDAr activation in
cortical and subcortical networks important for MMN generation.
In terms of clarifying the nature of the relationship between cannabis use
and MMN, this thesis replicated previous findings of smaller frequency MMN
amplitude [237] in a larger sample of heavier (average of 15.6 versus 8.8 joints per
week) and more protracted (average 9.6 versus 3.0 years of regular use) cannabis
users. Roser and colleagues [237] reported smaller frequency MMN amplitude in
a sub-group of heavier and longer-term users, and a linear association between
smaller frequency MMN amplitude and longer durations of cannabis use. Contrary
to these findings, we did not report any relationship between frequency MMN and
the duration or quantity of cannabis use. Instead, the development of frequency
MMN deficits may be a less sensitive index of cumulative exposure to cannabis in
our sample of heavier and more protracted users. These findings support the view
that heavy and prolonged cannabis use results in pathophysiological and
functional brain changes similar to the robust pattern of smaller frequency MMN
amplitudes reported in chronic schizophrenia patients [337].
Findings of smaller frequency MMN amplitude in regular cannabis users in
this thesis are based on a cross-sectional design and do not offer direct causal
evidence that repeated cannabis exposure reduces MMN amplitude. It may be,

145

Discussion

for example, that cannabis users in chapter four had reduced frequency MMN
amplitudes prior to the onset of use and that the results instead reflect a
vulnerability to use cannabis. There is yet to be a longitudinal investigation to
determine whether cannabis users, without history of psychosis, transition from
normal frequency MMN (relative to non-users) prior to the onset of use, to smaller
MMN amplitudes following prolonged exposure to cannabis. However, this
interpretation is less likely given that Roser and colleagues [237] report longer
durations of cannabis exposure with smaller frequency MMN amplitudes,
suggesting MMN deficits develop with ongoing use. Rather than smaller frequency
MMN amplitude indexing a pre-onset vulnerability to use cannabis, it is more likely
that findings in chapter four index the impairing effects of prolonged cannabis
exposure on frequency MMN processing.
Smaller frequency MMN amplitudes may index increased gyrification of
the tonotopic organisation of the auditory cortex (AC) following repeated
exposure to exogenous cannabinoids. This view is supported by previous findings
of abnormal gyrification and cortical thinning in cannabis users, who were of
similar age and duration of regular cannabis use to participants in chapter four
[306]. Frequency MMN deficits (and to a lesser extent, duration MMN) in chronic
schizophrenia patients has shown to be correlated with grey matter loss in the
auditory and frontal cortices [286]. These findings are consistent with a model of
increased age-related fractional anisotropy [367], cognitive decline [24] and
altered synaptic plasticity [250-253], with increasing disease progression in
schizophrenia patients. Following this, smaller frequency MMN amplitude in
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cannabis users in this thesis may index the effects of repeated cannabis exposure
in down-regulating CB1 receptors, resulting in NMDAr-mediated abnormal
gyrification of the auditory cortex, similar to that reported in chronic
schizophrenia (for example, see [286]).
Smaller duration MMN amplitudes may index functional impairment that is
more sensitive to the degree of cannabis exposure following prolonged periods of
use. The pattern of smaller duration MMN amplitude in regular users in this thesis
(chapter four) has since been replicated in a sample of tobacco-naïve regular
cannabis users [240]. Exogenous cannabinoids disrupt experience-dependent
alterations in neuronal excitation [322] and synaptic integration across brain
regions [325], which are necessary for neuronal plasticity and deviance detection.
In regular cannabis users, ongoing exposure may lead to NMDAr-mediated
alterations in cortico-thalamo networks in non-leminiscal pathways of the
auditory system, which are required for duration MMN processing [195, 210, 246,
313]. Smaller duration MMN amplitudes in this thesis (chapter four) were found
in the long-term user subgroup only, with smaller amplitudes being associated
with longer periods of daily (and regular) use in the overall sample of regular
cannabis users. These findings are consistent with patterns of smaller duration
MMN amplitude being associated with increased duration and frequency of
cannabis use in schizophrenia patients [215]. Further, they support the view that
smaller MMN amplitudes in response to duration deviants is more profound
following protracted and heavier patterns of cannabis use.
The nature of duration MMN deficits in regular cannabis users (chapter
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four) is contrary to the pattern of findings reported in schizophrenia. In chapter
four, smaller duration MMN amplitudes were associated with more protracted
cannabis use, while smaller duration MMN amplitudes in schizophrenia are
primarily found in individuals at risk for developing psychosis or early in the
prodrome [247, 249, 284]. It is unlikely that smaller duration MMN amplitude in
cannabis users in this thesis (chapter four) index a premorbid psychosis
vulnerability, as users had no history of psychosis despite their protracted use, and
instead are likely to represent a sample of cannabis users without existing
vulnerability. Differences in the pattern of duration MMN between long-term
cannabis users and schizophrenia suggest a common functional deficit with
different underlying neuropathology. Smaller duration MMN amplitudes have
been shown to index lower thalamic glutamate plus glutamine levels in the
prodromal stages of the illness [53], while our finding of smaller duration MMN
amplitude in chronic schizophrenia patients (chapter five) was associated with
greater negative symptoms, which is also thought to be mediated by
hypofunctional NMDArs [54]. Together, these findings suggest MMN is a sensitive
index of NMDAr hypofunction throughout the course of illness and further
clarification is required to determine differences in underlying mechanisms of
reduced MMN amplitude (as an index of NMDAr function), as well as their relation
to clinical symptoms, during different stages of the disorder.
Smaller duration MMN amplitude in long-term cannabis users (chapter
four) was associated with increased psychotic-like symptoms while intoxicated,
suggesting that ongoing endocannabinoid-mediated alterations in NMDAr
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function leads to downstream effects in neurotransmitter pathways such as
dopamine. These findings are consistent with the glutamatergic hypothesis
outlining a preliminary NMDAr hypofunction which leads to excessive dopamine
release in the mesolimbic pathway [53-55]. CB1 receptors have been show to
mediate the inhibition of glutamate release at excitatory neurons in the ventral
tegmental area [368]. Findings of acute intoxication symptoms in this thesis
(chapter four) are consistent with previous reports of smaller duration MMN
amplitude being associated with increased psychotic symptoms in non-clinical
individuals [369] and NMDAr antagonist models that induce psychotic symptoms
in individuals without psychiatric history [51, 56]. Although cannabis users in
chapter four did not develop psychosis (discussed above), these findings suggest
a common neurochemical mechanism for which long-term cannabis use might
lead to schizophrenia-like changes in the brain, particularly those associated with
conversion to psychosis [178, 248].
In determining the neurochemistry associated with smaller MMN
amplitudes in schizophrenia, findings in chapter five confirm that acute glycine
administration increases MMN amplitude in chronic patients. This suggests that
glycine crosses the blood-brain barrier to increase NMDAr neurotransmission and
supports the view that NMDAr hypofunction underlies robust MMN deficits
previously reported in schizophrenia [241]. The same low-dose glycine
administered in healthy controls (chapter six) favoured a trend towards increased
MMN amplitude, but this difference was not significant in the overall sample when
compared to placebo. A likely explanation for these reported differences is that
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some individuals in chapter six had no, or little, benefit from receiving glycine.
Although these studies are not directly comparable, together they support the
view that increasing synaptic glycine concentration is more beneficial in the
context of remediation, whereby those with lower baseline NMDAr function
(indexed by MMN), such as in schizophrenia, benefit from increased excitatory
neurotransmission following glycine administration.
MMN may be useful in stratifying neurobiological function as a predictor
of treatment response. The reported linear associations between baseline and
changes in MMN amplitude following low- and high-dose glycine (chapter six) are
consistent with the view that baseline NMDAr function mediates the effect of
glycine. Almost all participants in chapter six had reduced MMN amplitudes
following high-dose glycine, while findings were mixed (increases versus
decreases) following low-dose. It is possible this linear relationship indexes a dosedependent effect of glycine, mediated by baseline levels of NMDAr functioning
prior to treatment administration. However, caution is required when interpreting
this linear relationship due to potential bias towards the mean. It may be that
individuals with more extreme MMN amplitude values at baseline regress towards
the mean for post-glycine measurements, thereby biasing the change score.
Further research is required to confirm the effects of baseline NMDAr function in
mediating functional outcomes following neuronal target engagement of glycine.
Findings in chapter six confirm the nature of the relationship between
glycine and MMN is that of an Inverted-U dose-response curve. High-dose glycine
reduced MMN compared to small- and medium-doses, suggesting reduced
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efficacy of high-dose glycine to increase NMDAr neurotransmission in healthy
controls. This pattern is consistent with previous studies reporting decreased
cognitive performance [226, 365] and reduced NMDAr currents [342] at higher
synaptic glycine concentrations. Impaired pre-pulse inhibition, which is thought to
be mediated by dopaminergic function, has also been reported following higher
doses of glycine in patients with chronic schizophrenia [225, 359]. Contrary to
previous reports [225], high-dose glycine in chapter six did not reduce MMN
compared to placebo, suggesting that the high-dose condition did not ‘impair’
MMN generation in this study, but did reduced NMDAr function (indexed by
smaller MMN amplitudes) when compared to low- and medium-doses. Further
clarification of the functional significance of smaller MMN amplitude following
higher (compared to low and medium) doses of glycine is needed in order to
inform the potential risks of exceeding optimal synaptic glycine concentrations
within a therapeutic context.
Previous reports on the efficacy of increasing synaptic glycine
concentration in schizophrenia have been inconsistent, with supporting evidence
coming primarily from smaller independent trials [117, 122, 123] and mixed
findings reported in recent Phase-II versus Phase-III clinical trials [128]. Since the
publication of chapter five, two phase-III multi-centre trials of bitopertin were
reported in a cumulative sample of 1199 schizophrenia patients [370]. Following
24-weeks of treatment, bitopertin improved negative symptoms but did not show
superior efficacy when compared to placebo. Contrary to these findings, glycine
improved negative symptoms compared to placebo in this thesis, suggesting the
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need for continued investigation into the conditions for optimal treatment
efficacy. The sample of schizophrenia outpatients in chapter five were relatively
low on positive symptoms compared to previous studies [128] and may index a
more homogenous sample in relation to symptom profiles, particularly compared
to larger trials. Inconsistencies across studies suggest NMDAr-mediated
treatments may be beneficial in a subgroup of patients; however, categorising
patients based on broad diagnostic features does not appear to adequately
dissociate individuals who may benefit from increasing synaptic glycine
concentrations. Further to this, Beck and colleagues [2] raise concerns of
secondary negative symptoms inflating a placebo effect following NMDArmediated treatments, particularly in chronic patients. Utilising a placebo and
treatment-as-usual or waitlist group may help to further clarify the efficacy of
NMDAr-mediated treatments in schizophrenia.
Clinical findings in schizophrenia patients in this thesis (chapter five) report
improved PANSS-Total, PANSS-Negative and PANSS-General symptoms, and
favoured a trend towards improved depressive symptoms on the Calgary
Depression Rating Scale (CDRS) following 6-weeks of glycine treatment. These
findings support previous studies reporting improved symptoms following glycine
[115-117, 121-123], D-Serine [118, 119] and NAC [120] in schizophrenia. While a
full dissociation between primary and secondary negative symptoms is not
feasible in this study design, scores on the CDRS and PANSS-General symptom
scales were not associated with baseline or changes in MMN amplitude following
treatment. These findings provide indirect support for an independent association
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of primary and secondary negative symptoms within a model of NMDAr
hypofunction, but confirmatory research is needed to verify this dissociation.
Following glycine treatment, there were no changes in functional impairment as
assessed by the Work and Social Adjustment Scale, suggesting that changes in
negative symptoms were not secondary to change in social functioning in this
thesis. It may be that longer trials of NMDAr agents are required to facilitate more
gross functional changes that are secondary to negative symptom improvement.
The current findings support the need to investigate the nature of more global
improvements in schizophrenia following increased glutamatergic function.
In determining the relationship between MMN and clinical symptoms in
schizophrenia in this thesis, smaller baseline MMN amplitude was found to be
associated with greater severity in negative symptoms (chapter five). MMN has
previously been associated with illness duration and premorbid, cognitive and
psychosocial functioning [243, 284, 371], and in some studies with improved
clinical symptoms [257, 339]. This finding is in line with the glutamatergic
hypothesis and pathophysiological model of NMDAr hypofunction [53-55]
involved in the generation of negative symptoms. In further support of this view,
baseline duration MMN amplitudes predicted (at trend level) the degree of
improved negative symptoms following 6-weeks of adjunct glycine treatment
(chapter six). Together, these findings support the use of MMN as an index of
NMDAr deficit severity related to the pathophysiology of negative symptoms and
suggest the need to stratify patients based on neurobiological dysfunction in order
to achieve optimal treatment efficacy.
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Findings of an Inverted-U relationship between glycine dose and MMN
(chapter six) suggest there may be an optimal window for clinical benefits
following NMDAr-mediated treatments. The state of NMDAr hypofunction [54]
and reduced synaptic glycine concentrations [357] in schizophrenia may allow
greater margin for increasing synaptic concentrations, before reaching saturation.
This view suggests that the optimal dose to increase NMDAr function is higher in
schizophrenia compared to controls. However, given the heterogeneity of NMDAr
function within schizophrenia, these findings also suggest that higher doses may
lead to more-varied treatment outcomes; higher doses may be beneficial in
restoring NMDAr hypofunction in patients with low NMDAr neurotransmission,
while the same dose administered in patients with relatively normal NMDAr
functioning may lead to saturation of glycine at the synapse. If this is the case, only
a subset of patients would be expected to benefit from higher doses of NMDArmediated treatments. This view is further supported by findings of smaller
duration MMN amplitudes predicting greater improvements in negative
symptoms in schizophrenia patients (chapter five), whereby those with smaller
MMN amplitudes experienced greater clinical benefits in negative symptoms
following glycine treatment.
MMN appeared sensitive to alterations in NMDAr function following acute
glycine administration in schizophrenia (chapter five) and healthy controls
(chapter six) in this thesis, however no differences in MMN were found following
6-weeks of glycine treatment. This finding suggests that the efficacy of glycine to
increase glutamatergic function did not extend to long-term plasticity changes in
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auditory cortical networks involved in MMN generation, as was inferred from
findings in regular cannabis users in chapter five. An alternative explanation is that
changes in duration MMN amplitude are a more sensitive index to state changes
in NMDAr function, while improved clinical symptoms index the cumulative
effects of glycine. It is noteworthy that glycine was not administered on the day of
6-week follow-up testing in this thesis. It is possible that although acute glycine
administration altered NMDAr function, repeated administration of adjunct
glycine treatment may not lead to long-term plasticity changes over this time
period. If so, this would mean that the therapeutic benefits reported in chapter
five are due to cumulative exposure or possibly secondary effects on other
neurochemical systems, rather than long-term changes to the NMDAr system
itself. Consistent with this interpretation, altered duration MMN processing was
associated with more prolonged and heavier periods of cannabis use in chapter
five, whereby group differences in duration MMN amplitude were reported for
the long-term user group only.

7.4

Limitations and Future Direction

Progressive decline in MMN amplitude, particularly in earlier stages of cannabis
use, may overlap with models of advanced age-related decline reported in
schizophrenia (for example, see [250]). Findings in regular cannabis users in this
thesis are based on a cross-section design and are limited in offering direct causal
evidence between repeated cannabis exposure and reduced MMN amplitude.
Future studies could profitably utilise longitudinal methods to investigate the
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biological mechanisms of repeated exposure to exogenous cannabinoids on
progressive structural alterations contributing to MMN deficits reported in regular
cannabis users. Given emerging evidence that increased cannabis dependence
severity is associated with dopaminergic dysregulation [372] in neuronal pathways
implicated in the pathophysiology of schizophrenia, future studies could control
for changing severity of cannabis dependence. These findings may inform
underlying mechanisms of positive and negative symptoms, and similarities in
NMDAr-mediated structural and functional alterations between schizophrenia
and regular cannabis users.
The concentrations of exogenous cannabinoids in cannabis plant matter
used by participants in this thesis were not measured or controlled. Smaller MMN
amplitudes in regular cannabis users (chapter four) suggest an ‘impairing’ effect
of cannabis on NMDAr function in otherwise healthy individuals. Increasing the
concentration of CBD in cannabis plant matter may reduce these ‘impairing’
effects. The purported therapeutic benefits of CBD for schizophrenia may increase
NMDAr function in patients, as was demonstrated in chapter five following lowdose glycine (indexed by changed in MMN). It was beyond the scope of the current
thesis to examine the therapeutic efficacy of cannabis containing higher
concentrations of CBD. Therefore, the direction of cannabis effects reported here
should be interpreted with caution, particularly within the context of CBD as an
alternative treatment for psychotic-related disorders.
This thesis (chapter five) failed to replicate smaller frequency MMN
amplitude in chronic schizophrenia patients and was therefore unable to
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generalise the effects of glycine across a broader framework of MMN deviance
detection. Changes in experience-dependent plasticity has been demonstrated for
frequency discrimination [350], whereby reorganisation of neuronal populations
increase sensitivity to relevant stimuli and generate additional neuronal responses
to trained frequencies. The malleability of this structural organisation is likely
susceptible to pharmacological modulation, as was inferred from findings in
regular cannabis users in chapter four. Future studies should investigate the
effects of NMDAr-mediated treatments on frequency MMN processing, as it may
be a more sensitive index (compared to duration MMN) of the cumulative effects
following increased NMDAr function. Such findings may inform the differential
patterns of each MMN deviant type throughout the chronicity of schizophrenia
and the differential patterns of frequency versus duration MMN processing which
were observed following regular cannabis use in this thesis.
The low number of positive symptoms endorsed by schizophrenia
outpatients in chapter five may not adequately index the potential therapeutic
benefits of increasing synaptic glycine concentrations in treating this symptom
domain. Research is required to map narrowly defined symptoms within
schizophrenia. Determining the relationship between MMN as a marker of NMDAr
function and its relationship with narrowly defined symptoms, particularly
negative symptom sub-domains, may inform the transdiagnostic utility of MMN
to index treatment-specific targets, rather than relying on broader diagnostic
categorisation (which may be too broad to be relevant). Neurocomputational
models may better inform the mechanism of discrete symptom clusters, including
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their primary and secondary nature, and facilitate greater accuracy in guiding early
treatment interventions.
Evidence of an Inverted-U dose-response relationship between glycine and
MMN amplitude in this thesis is based on single-dose administration. The effects
of long-term repeated dosing of glycine is unclear and may alter the efficacy of
glycine to increase NMDAr function following repeated administration. It would
thus be important to clarify whether the acute Inverted-U dose-response
relationship between glycine and MMN remains when administered repeatedly in
a model of treatment efficacy. Further, the nature of the dose-response
relationship between glycine and MMN in this thesis was not directly examined in
schizophrenia. It is unclear whether the Inverted-U curve is present in
schizophrenia patients, or whether there is a linear increase in MMN amplitude
following increased glycine dose. Replicating the nature of the Inverted-U
relationship in schizophrenia may better inform optimal treatment doses to
increase NMDAr hypofunction in schizophrenia and further inform the
heterogeneity of treatment outcomes at higher glycine doses.
A methodological limitation in our examination of the glycine doseresponse effect in healthy controls (chapter six), is comparability to previous
findings [225]. Our use of a change variable to examine the effects of glycine
(change from baseline to post-drug administration) aimed to control for potential
differences in baseline MMN amplitude across treatment sessions. Following highdose glycine, we report reduced MMN amplitudes in individuals with higher
baseline MMN. However, the use of a change score may have created a floor-type
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effect in the low baseline group, while the longer testing period, including baseline
and post-drug measures, may have created a regression towards the mean,
reducing the sensitivity of our measure to index glycine-mediated changes in
MMN. Future studies should investigate the significance of reduced MMN relative
to other cognitive performance measures sensitive to functional outcomes in
schizophrenia.
While this thesis informs the nature of the relationship between NMDAr
function and MMN amplitude, these findings are limited in informing the
mechanisms underlying changes in MMN generation. Utilising MRI brain structural
analysis to support current source density mapping may be a useful way to
examine the effects of pharmacological intervention and inform the mechanisms
for different deviant types. A combined spectral decomposition analysis of the
MMN waveform may inform the independent contributions of cortico-cortico and
cortico-thalamic networks in altering MMN generation, particularly following
increased synaptic glycine concentration. These methods may aid further
understanding of the independent and overlapping pathways involved in
frequency versus duration MMN processing, and inform differential findings
reported throughout the chronicity of schizophrenia and following prolonged
periods of cannabis use, as well as their sensitivity in predicting treatment
outcomes.
A limitation of glycine and other NMDAr agonists, such as D-serine, is the
variability they introduce from metabolic processes and the large doses required
to cross the blood-brain barrier. It may be useful to replicate the MMN findings in
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this thesis following administration of GT1-RIs, such as bitopertin and sarcosine.
These treatments increase synaptic glycine concentrations by blocking the
reuptake of glycine in the synapse. Determining whether GT1-RIs have a similar
effect to that of glycine will provide important information as to the mechanism
of their effect. It may be, for example, that GT1-RIs require sufficient endogenous
glycine to be efficacious, and that lower endogenous glycine levels may limit their
ability to improve NMDAr function. Such information would be important for
tailoring effective treatments for the heterogeneity present in schizophrenia.
While this thesis aimed to determine the nature of the relationship
between MMN and NMDAr function, it is limited in informing the mechanisms of
change in neuronal functioning. This thesis concludes that altering NMDAr
function may result in different neuronal functional outcomes and that such
variabilities in neuronal response is likely involved in the heterogeneity of clinical
treatment efficacy in schizophrenia following NMDAr-mediated treatments.
However, the findings used to infer this relationship, including regular cannabis
use and the dose-response effects of glycine, were not directly examined in
schizophrenia patients. The nature of the relationship between MMN, regular
cannabis use and glycine dose-dependence may differ within the context of
NMDAr hypofunction in schizophrenia patients. Therefore, further studies are
required to confirm the stability of these MMN findings in schizophrenia, in order
to understand their implications for indexing neuronal target engagement and
clinical efficacy following NMDAr-mediated treatments.
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7.5

Conclusion

This thesis demonstrates that MMN is a sensitive biomarker to index the
neurobiological state of NMDAr function. Chapter four provides indirect evidence
of endocannabinoid-mediated alterations of NMDArs in auditory cortical
networks important for MMN generation. Acute administration of glycine in
chapter five increased MMN in schizophrenia patients and the same pattern was
observed (at trend level) in chapter six following low-dose glycine administered in
healthy controls. An Inverted-U dose-response relationship between glycine and
MMN suggests there is an optimal therapeutic window for glycine to increase
NMDAr function, beyond which treatment efficacy is reduced. Together, these
findings indicate that changes in MMN index alterations in NMDAr function, which
may arise from pre or post-synaptic mechanisms. Further, they support the utility
of MMN to index changes in NMDAr excitability following neuronal target
engagement of NMDAr-mediated treatments. Indexing change in NMDAr function
following treatment may identify subgroups of patients who will (and won’t)
benefit from increasing synaptic glycine concentrations.
The efficacy of glycine to increase NMDAr function in this thesis appeared
greater in the context of remediation, whereby increasing synaptic glycine
concentration improved MMN in models of NMDAr hypofunction. Smaller
duration and frequency MMN amplitudes were associated with intoxicated
psychotic-like symptoms in long-term regular cannabis users, while smaller
duration MMN amplitude in schizophrenia was associated with greater severity of
negative symptoms and predicted negative symptom improvement (trend-level)
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following glycine treatment. These findings suggest that MMN is a useful index to
stratify core phenotypes based on biological dysfunction, rather than broad
diagnostic criteria. It would be useful for future studies to replicate findings of an
Inverted-U dose-response relationship for MMN following administration of
glycine-reuptake inhibitors, such as bitopertin. Clarifying this relationship would
assist in tailoring effective treatment and further inform the heterogeneity of
clinical treatment response in schizophrenia.
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